Abstract
We hypothesized that heightened systemic inflammation contributes to the increased rate of cardiovascular events in HIV-infected patients not receiving combination antiretroviral therapy. We performed a pilot trial to assess the effects of the nuclear factor-kappaB inhibitor salsalate on flow-mediated dilation of the brachial artery, a measure of endothelial function. Flow-mediated dilation significantly improved after 8 weeks of salsalate. However, hepatotoxicity occurred frequently. Research using alternative agents is warranted to examine the role of inflammation in HIV-related cardiovascular disease.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Brachial Artery / physiology
-
Cardiovascular Diseases / physiopathology
-
Cardiovascular Diseases / virology*
-
Endothelium, Vascular / physiopathology*
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / physiopathology
-
Humans
-
Liver / drug effects
-
Male
-
Middle Aged
-
NF-kappa B / antagonists & inhibitors*
-
Pilot Projects
-
Salicylates / adverse effects
-
Salicylates / therapeutic use*
-
Vasodilation / drug effects
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
NF-kappa B
-
Salicylates
-
salicylsalicylic acid